Back to News
Market Impact: 0.12
Iovance Biotherapeutics Names Noah Berkowitz CMO
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Iovance Biotherapeutics appointed Noah Berkowitz as chief medical officer, effective September 30. The executive appointment is a routine governance update with limited near-term implications for the company’s operating outlook or share price.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
IOVA0.15
More News
- Can Trump Oust Powell From the Fed Board? What to Know
- Paramount promised 30 movies a year to win Warner Bros. Losing Miramax if it fails may not scare it
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- AI’s biggest players promise to police themselves at the White House
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Boeing engineers and technical workers approve new contract, avoiding strike
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features and More Sources for Document Search
- How to Evaluate AI Report Writers for Financial Analysis